• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
HEP-Net opinion on the management of ascites and its complications in the setting of decompensated cirrhosis in the resource constrained environment of Pakistan.HEP-Net关于在巴基斯坦资源有限环境下失代偿期肝硬化患者腹水及其并发症管理的意见。
Pak J Med Sci. 2020 Jul-Aug;36(5):1117-1132. doi: 10.12669/pjms.36.5.2407.
2
Current Management of the Complications of Cirrhosis and Portal Hypertension: Variceal Hemorrhage, Ascites, and Spontaneous Bacterial Peritonitis.肝硬化和门静脉高压并发症的当前管理:静脉曲张出血、腹水和自发性细菌性腹膜炎
Dig Dis. 2016;34(4):382-6. doi: 10.1159/000444551. Epub 2016 May 11.
3
Management of ascites and hepatorenal syndrome.腹水和肝肾综合征的管理。
Hepatol Int. 2018 Feb;12(Suppl 1):122-134. doi: 10.1007/s12072-017-9815-0. Epub 2017 Aug 23.
4
Optimal Management of Cirrhotic Ascites: A Review for Internal Medicine Physicians.肝硬化腹水的优化管理:内科医师综述
J Transl Int Med. 2020 Dec 31;8(4):220-236. doi: 10.2478/jtim-2020-0035. eCollection 2020 Dec.
5
EVALUATION OF PROGNOSTIC FACTORS IN DECOMPENSATED LIVER CIRRHOSIS WITH ASCITES AND SPONTANEOUS BACTERIAL PERITONITIS.伴有腹水和自发性细菌性腹膜炎的失代偿期肝硬化预后因素评估
Rev Med Chir Soc Med Nat Iasi. 2015 Oct-Dec;119(4):1018-24.
6
Assessing the risk of decompensation by ascites and spontaneous bacterial peritonitis in cirrhosis.评估肝硬化患者腹水及自发性细菌性腹膜炎导致失代偿的风险。
Rev Med Chir Soc Med Nat Iasi. 2014 Apr-Jun;118(2):320-6.
7
Presentation and complications associated with cirrhosis of the liver.肝硬化的临床表现及相关并发症。
Curr Med Res Opin. 2015 May;31(5):925-37. doi: 10.1185/03007995.2015.1021905.
8
Impact of Hyponatremia on Morbidity, Mortality, and Resource Utilization in Portal Hypertensive Ascites: A Nationwide Analysis.低钠血症对门静脉高压性腹水患者发病率、死亡率及资源利用的影响:一项全国性分析
J Clin Exp Hepatol. 2022 May-Jun;12(3):871-875. doi: 10.1016/j.jceh.2021.10.145. Epub 2021 Oct 28.
9
Review article: Management of ascites and associated complications in patients with cirrhosis.综述文章:肝硬化患者腹水及相关并发症的管理
Aliment Pharmacol Ther. 2007 Dec;26 Suppl 2:183-93. doi: 10.1111/j.1365-2036.2007.03482.x.
10
Analysis of Risk Factors for Patients with Liver Cirrhosis Complicated with Spontaneous Bacterial Peritonitis.肝硬化合并自发性细菌性腹膜炎患者的危险因素分析
Iran J Public Health. 2018 Dec;47(12):1883-1890.

引用本文的文献

1
Validation and exploratory factor analysis of Urdu Version of Chronic Liver Disease Questionnaire.《慢性肝病问卷》乌尔都语版本的效度验证与探索性因素分析
Pak J Med Sci. 2023 Jan-Feb;39(1):117-127. doi: 10.12669/pjms.39.1.6602.

本文引用的文献

1
Standardized approach of albumin, midodrine and octreotide on hepatorenal syndrome treatment response rate.白蛋白、米多君和奥曲肽治疗肝肾综合征的标准化方法及其治疗反应率
Eur J Gastroenterol Hepatol. 2021 Jan;33(1):102-106. doi: 10.1097/MEG.0000000000001700.
2
Inpatient Mortality Benefit with Transjugular Intrahepatic Portosystemic Shunt for Hospitalized Hepatorenal Syndrome Patients.经颈静脉肝内门体分流术治疗住院肝肾综合征患者的住院病死率获益。
Dig Dis Sci. 2020 Nov;65(11):3378-3388. doi: 10.1007/s10620-020-06136-2. Epub 2020 Feb 15.
3
Is renal replacement therapy necessary in deceased donor liver transplantation candidates with hepatorenal syndrome?: a 2-year experience at a high-volume center.肝肾综合征的已故供体肝移植候选者是否需要肾脏替代治疗?:一家大型中心的两年经验
Ann Surg Treat Res. 2020 Feb;98(2):102-109. doi: 10.4174/astr.2020.98.2.102. Epub 2020 Jan 31.
4
Urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a Marker of Diabetic Nephropathy in Type 1 Diabetic Patients.尿中性粒细胞明胶酶相关脂质运载蛋白(NGAL)作为1型糖尿病患者糖尿病肾病的标志物
Clin Lab. 2020 Jan 1;66(1). doi: 10.7754/Clin.Lab.2019.190326.
5
Improvement in Quality of Life and Decrease in Large-Volume Paracentesis Requirements With the Automated Low-Flow Ascites Pump.自动化低流量腹水泵可改善生活质量并减少大量腹腔穿刺术需求。
Liver Transpl. 2020 May;26(5):651-661. doi: 10.1002/lt.25724. Epub 2020 Mar 22.
6
Thymoquinone and curcumin combination protects cisplatin-induced kidney injury, nephrotoxicity by attenuating NFκB, KIM-1 and ameliorating Nrf2/HO-1 signalling.姜黄素和姜黄素有组合保护顺铂诱导的肾损伤、肾毒性,减轻 NFκB、KIM-1 并改善 Nrf2/HO-1 信号通路。
J Drug Target. 2020 Nov;28(9):913-922. doi: 10.1080/1061186X.2020.1722136. Epub 2020 Feb 5.
7
Treatment for ascites in adults with decompensated liver cirrhosis: a network meta-analysis.失代偿期肝硬化成人腹水的治疗:一项网状Meta分析。
Cochrane Database Syst Rev. 2020 Jan 16;1(1):CD013123. doi: 10.1002/14651858.CD013123.pub2.
8
Severity of Ascites Is Associated with Increased Mortality in Patients with Cirrhosis Secondary to Biliary Atresia.胆汁淤积性肝硬化患者腹水严重程度与死亡率增加相关。
Dig Dis Sci. 2020 Nov;65(11):3369-3377. doi: 10.1007/s10620-019-06029-z. Epub 2020 Jan 6.
9
Diagnosis and management of renal dysfunction in patients with cirrhosis.肝硬化患者肾功能障碍的诊断和治疗。
Expert Rev Gastroenterol Hepatol. 2020 Jan;14(1):1-7. doi: 10.1080/17474124.2020.1708190. Epub 2019 Dec 30.
10
Paracentesis-Induced Circulatory Dysfunction With Modest-Volume Paracentesis Is Partly Ameliorated by Albumin Infusion in Acute-on-Chronic Liver Failure.中等量腹水穿刺术诱导的循环功能障碍部分可通过白蛋白输注改善急性加重期慢性肝衰竭患者的循环功能障碍。
Hepatology. 2020 Sep;72(3):1043-1055. doi: 10.1002/hep.31071. Epub 2020 Jul 9.

HEP-Net关于在巴基斯坦资源有限环境下失代偿期肝硬化患者腹水及其并发症管理的意见。

HEP-Net opinion on the management of ascites and its complications in the setting of decompensated cirrhosis in the resource constrained environment of Pakistan.

作者信息

Ali Bushra, Salim Adnan, Alam Altaf, Zuberi Bader Faiyaz, Ali Zeeshan, Azam Zahid, Kamani Lubna, Farooqi Javed Iqbal, Salih Muhammed, Nawaz Arif Amir, Chaudhry Asad Ali, Hashmi Zahid Yasin, Siddique Masood

机构信息

Bushra Ali, Fatima Memorial Medical and Dental College, Lahore, Pakistan.

Adnan Salim, Shaikh Zayed Postgraduate Medical Institute, Lahore, Pakistan.

出版信息

Pak J Med Sci. 2020 Jul-Aug;36(5):1117-1132. doi: 10.12669/pjms.36.5.2407.

DOI:10.12669/pjms.36.5.2407
PMID:32704299
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7372671/
Abstract

Approximately one half of patients develop ascites within 10 years of diagnosis of compensated cirrhosis. It is a poor prognostic indicator, with only 50% surviving beyond two years. Mortality worsens significantly to 20% to 50% at one year if the ascites becomes refractory to medical therapy. Pakistan has one of the highest prevalence of viral hepatitis in the world and patients with ascites secondary to liver cirrhosis make a major percentage of both inpatient and outpatient burden. Studies indicate that over 80% of patients admitted with ascites have liver cirrhosis as the cause. This expert opinion suggests proper assessment of patients with ascites in the presence of underlying cirrhosis. This expert opinion includes appropriate diagnosis and management of uncomplicated ascites, refractory ascites and complicated ascites (including spontaneous bacterial peritonitis (SBP) ascites, hepatorenal syndrome (HRS) and hyponatremia. The purpose behind this expert opinion is to help consultants, postgraduate trainees, medical officers and primary care physicians optimally manage their patients with cirrhosis and ascites in a resource constrained setting as is often encountered in a developing country like Pakistan.

摘要

约一半的患者在代偿期肝硬化确诊后的10年内会出现腹水。它是一个预后不良的指标,只有50%的患者能存活超过两年。如果腹水对药物治疗产生耐药,一年的死亡率会显著恶化至20%至50%。巴基斯坦是世界上病毒性肝炎患病率最高的国家之一,肝硬化继发腹水的患者在住院和门诊负担中占很大比例。研究表明,超过80%因腹水入院的患者病因是肝硬化。本专家意见建议对存在潜在肝硬化的腹水患者进行恰当评估。本专家意见包括对单纯性腹水、顽固性腹水和复杂性腹水(包括自发性细菌性腹膜炎(SBP)腹水、肝肾综合征(HRS)和低钠血症)进行适当的诊断和管理。本专家意见的目的是帮助会诊医生、研究生学员、医务人员和初级保健医生,在像巴基斯坦这样的发展中国家经常遇到的资源有限的情况下,对肝硬化和腹水患者进行最佳管理。